Calculate Cancer Cell Fraction

Estimate cancer cell fraction (CCF) from observed variant allele frequency (VAF), tumor purity, local copy number, and mutant allele multiplicity assumptions.

How to Calculate Cancer Cell Fraction (CCF): A Practical, Clinically Informed Guide

Cancer cell fraction (CCF) is one of the most useful concepts in modern cancer genomics because it helps you estimate how widely a mutation is distributed across malignant cells in a sample. In simple terms, CCF answers this question: “What fraction of the cancer cells carry this variant?” This is critically different from variant allele frequency (VAF), which only tells you the fraction of sequence reads containing the variant. A mutation can have the same VAF in two different samples but represent very different biological realities if purity and copy number states differ.

CCF is often used in molecular tumor boards, clonal evolution studies, longitudinal liquid biopsy interpretation, resistance tracking, and translational research where distinguishing clonal from subclonal variants can influence mechanistic hypotheses and treatment strategy discussions. The calculator above provides a transparent approximation using a widely applied framework that adjusts observed VAF by tumor purity and locus-specific copy number.

Why VAF Alone Is Not Enough

VAF is shaped by at least four major factors: tumor purity, local copy number, mutation multiplicity, and sampling plus sequencing noise. Suppose a mutation appears at 20% VAF. If the sample has high purity and diploid copy number, that mutation may be subclonal. But in a low-purity specimen, the same 20% VAF could actually represent a largely clonal event diluted by normal DNA. Without purity and copy-number context, VAF can be misleading for phylogenetic interpretation.

• Purity effect: Normal-cell admixture lowers observed VAF for tumor-derived variants.
• Copy-number effect: Gains and losses alter denominator and expected read proportions.
• Multiplicity effect: Mutation present on multiple copies raises expected VAF.
• Technical effect: Depth, mapping quality, and platform error profiles influence confidence.

Formula Used in This Calculator

This calculator estimates CCF with the relationship:

CCF = [VAF × (Purity × Total CN + (1 – Purity) × 2)] / (Purity × Mutant Copy Number)

where VAF and purity are converted to fractions (not percentages) during computation. The term (1 – Purity) × 2 assumes diploid normal-cell background. This approximation is commonly used in practical analyses, especially when purity and copy number estimates are already available from tools such as FACETS, ABSOLUTE-like approaches, CNV pipelines, or pathology-informed estimates.

Interpreting Output Carefully

In many workflows, CCF near 1.0 suggests a clonal mutation, while lower values suggest subclonality. However, interpretation should remain probabilistic rather than absolute. If your estimate exceeds 1.0, that usually indicates one of these situations: incorrect multiplicity assumption, imprecise purity estimate, local copy-number complexity, or sequencing bias. In practice, analysts often iterate multiplicity assumptions and compare model fit to neighboring loci and broader copy-number context.

1. Start with pathology-informed purity estimates and orthogonal molecular estimates.
2. Use locus-specific copy number when possible, not genome-wide average ploidy only.
3. Evaluate whether multiplicity 1 or higher better fits observed VAF.
4. Flag low-depth or low-quality calls before assigning clonal status.
5. Integrate serial timepoint data when available to validate clonal trajectories.

Real-World Scale of Data Supporting CCF-Based Thinking

CCF methods gained traction because large international efforts generated enough sequencing data to reveal recurrent clonal architecture patterns across cancer types. The projects below are foundational for modern interpretation standards and benchmarking approaches.

Program	Reported Scale	Relevance to CCF Interpretation
The Cancer Genome Atlas (TCGA)	33 tumor types; over 11,000 cases profiled	Established broad somatic landscape and tumor-type mutation context for clonal vs subclonal reasoning.
PCAWG (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes)	2,658 whole cancer genomes across 38 tumor types	Enabled high-resolution clonal structure and timing analyses in whole-genome space.
AACR Project GENIE	More than 190,000 sequenced tumor samples shared from international centers	Supports real-world mutational prevalence and contextual interpretation in clinical sequencing datasets.

These numbers matter because robust CCF interpretation depends on broad empirical baselines. A borderline CCF in a rare tumor context may carry different implications than the same estimate in a heavily characterized disease setting with rich longitudinal evidence.

Expected VAF and Copy-Number Context

A useful companion concept is the expected VAF if the mutation were fully clonal under the selected purity and multiplicity assumptions. The calculator reports this value. If observed VAF is substantially below expected clonal VAF, subclonality becomes more likely. If it is close, clonal presence is more plausible, though still contingent on confidence intervals and noise sources.

For example, with purity 60%, total copy number 2, and one mutated copy, expected clonal VAF is roughly 30%. If observed VAF is 15%, CCF would be around 0.5, suggesting the mutation is present in about half of malignant cells under the model assumptions.

Technical and Biological Caveats You Should Not Ignore

• Purity uncertainty: Histology and computational purity can diverge meaningfully.
• Subclonal CNAs: If copy number itself is heterogeneous, simple formulas can over-simplify reality.
• LOH states: Loss of heterozygosity can strongly shift expected allele fractions.
• Tumor heterogeneity: Multiregion sampling often reveals branch-specific variants missed by single-biopsy models.
• ctDNA dynamics: In plasma, shedding differences across lesions can decouple blood VAF from tissue clonality.

Analytical Factor	Typical Practical Range	Impact on CCF Stability
Sequencing depth (targeted panel)	~300x to 1000x+	Higher depth improves confidence for low-VAF variants and narrows uncertainty bands.
Approximate short-read base error rates	~0.1% to 1% raw context dependent	Sets practical lower detection floor and influences low-frequency variant filtering.
Minimum tumor fraction often sought in clinical solid-tumor assays	Frequently around 20% or higher input quality threshold (lab dependent)	Low purity can mask clonal variants and make CCF estimates unstable.

Values above are representative operational ranges reported across laboratories and publications; exact acceptance criteria vary by platform, assay design, and accreditation protocol.

Step-by-Step Workflow for Better CCF Estimation

1. Confirm variant quality: depth, strand balance, mapping quality, and artifact filters.
2. Obtain best-available tumor purity estimate from pathology and computational pipelines.
3. Use locus-level copy number rather than broad sample-level averages whenever possible.
4. Test multiple multiplicity scenarios and check whether inferred CCF remains biologically plausible.
5. Compare with neighboring driver events and known truncal mutations.
6. In longitudinal samples, inspect whether CCF shifts are coherent with treatment history.

When to Use This Calculator vs. Full Probabilistic Models

This calculator is ideal for rapid interpretation, educational use, and first-pass tumor-board discussions. It makes assumptions explicit and gives immediate intuition. For publication-grade phylogenetic inference, especially in highly aneuploid tumors or deeply branched evolution, analysts should generally use probabilistic models that propagate uncertainty and incorporate multiple variants jointly. Still, quick CCF approximations remain extremely useful for triage and communication.

Authoritative Reference Links

• National Cancer Institute (.gov): Cancer biology fundamentals
• National Human Genome Research Institute (.gov): Genomics resources and standards
• SEER Program, NCI (.gov): Population cancer statistics

Bottom Line

To calculate cancer cell fraction reliably, you must integrate VAF with purity and copy-number context. CCF is not just a mathematical transformation; it is a biological inference that should be interpreted with technical caution and clinical context. Used correctly, it helps distinguish truncal from branch mutations, supports resistance tracking, and improves the interpretability of genomic findings across tissue and blood-based testing.